According to Bloomberg.com, the six research firms that keep tabs on Progyny, Inc. (NASDAQ: PGNY) have, on average, recommended that investors “Moderately Buy” the company’s stock, which they have rated as a “Moderate Buy.” The vast majority of financial analysts have suggested that investors purchase the stock, and only one of them has suggested that investors keep the same number of holdings they already have. In addition, brokerage firms that have updated their stock coverage in the past year have assigned the stock a one-year target price that is, on average, $62.80 higher than where it is currently trading.
The topic of PGNY has been the subject of many reports compiled by analysts. The results of a study report on sexism directed toward women to the general public on September 7 by Truist Financial. They gave the stock a “buy” rating and established a price target of $56.00. In a research note distributed on September 15, KeyCorp announced that the company would start covering Progyny shares. They have provided the company with an “overweight” rating and have determined that a price objective of $55.00 is appropriate for it.
The ChairmanChairman of the company, David J. Schlanger, sold 67,779 shares of the company’s stock on September 7, which brings us to another piece of news about Progyny. As a result of the purchase of the shares, a total expenditure of $2,674,559.34 was made, with the average price of each share coming in at $39.46. After the deal’s completion, the ChairmanChairman of the board is now the owner of 82,548 shares, which have an approximate value of $3,257,344.08. You will be taken to a document submitted to the Securities and Exchange Commission if you select this link and click it. This document contains additional information about the transaction. The ChairmanChairman of the company, David J. Schlanger, sold 67,779 shares of the company’s stock on September 7, which brings us to another piece of news about Progyny. As a result of the purchase of the shares, a total expenditure of $2,674,559.34 was made, with the average price of each share coming in at $39.46.
After the deal’s completion, the ChairmanChairman of the board is now the owner of 82,548 shares, which have an approximate value of $3,257,344.08. You will be taken to a document submitted to the Securities and Exchange Commission if you select this link and click it. This document contains additional information about the transaction. On July 6, Norman Payson, a company director, sold 6,618 shares of the company’s stock. The transaction took place on Wednesday. A total of $194,436.84 was spent on the acquisition of the stock, which resulted in an average price of $29.38 per share paid for the transaction. As a direct result of the transaction, the director now owns 437,884 shares. The total value of these shares is $12,865,000.00. Disclosures that are related to the sale might be found in this section of the website. In the preceding three months, business insiders sold a total of 213,154 shares of company stock for a sum of $8,574,354. These business insiders hold 14.04 percent of the company’s total shares of stock.
Recent transactions involving PGNY shareholdings have resulted in modifications made by various institutional investors, including hedge funds and other types of investment vehicles. Baillie Gifford & Co. increased the percentage of Progyny shares held by 337,578.8% during the first three months of the year. Baillie Gifford & Co. now directly owns a total of 1,337,208 shares in the company, which has a value of $68.732 million after purchasing an additional 1,336,812 shares in the company during the most recent quarter. This gives the company a market capitalization of $68.732 million. In the first quarter of 2018, American Century Companies Inc. increased the proportion of Progyny it owned by 52.0 percentage points. American Century Companies Inc. now has 3,532,054 shares of the company’s stock, which are currently valued at $181,548,000 after purchasing an additional 1,209,053 shares during the most recent quarter. This brings the total number of shares owned by the company to 3,532,054. During the second quarter, Thrivent Financial for Lutherans observed a rise in the value of its assets in Progyny, 74.6%. Thrivent Financial for Lutherans now has a total of 2,171,417 shares of the company’s stock, which are currently valued at $63,080,000 following the purchase of an additional 927,692 shares during the most recent quarter. Thrivent Financial for Lutherans has owned the company’s stock for a cumulative total of 66 years. Riverbridge Partners LLC increased its ownership of Progyny by 87.7% during the first quarter of the fiscal year through the purchase of additional shares. Following the purchase of an additional 712,722 shares during the most recent quarter, Riverbridge Partners LLC now owns a total of 1,525,055 shares of the company, which has a value of $78,388,000. This brings the total number of shares owned by the company to 1,525,055. And finally, during the second quarter, Millennium Management LLC increased its holdings in Progyny by 2,646.2%. This was an addition to the investment portfolio that the company maintains. After purchasing an additional 609,234 shares during the most recent quarter, Millennium Management LLC now has a total of 632,257 shares worth $18,367,000. This brings the total number of shares that it owns in the company to 632,257. The company’s stock makes up 88.64% of all institutional investors’ holdings.
The price of one share of PGNY common stock was $37.06 as of the market close on Friday. A price-to-earnings ratio of 80.57, a price-to-earnings-growth ratio of 9.18, and a beta value of 1.67 are all characteristics of the stock in question. The company’s total value, as represented by its market capitalization, is $3.41 billion. The price of Progyny hit a low of $25.67 during the past year, while it reached a high of $68.32 during the same period. The stock price is currently $39.42, which is higher than the 50-day simple moving average of $37.70 and lower than the 200-day simple moving average of $37.70. At the moment, one share of stock can be purchased for $39.42.
On Thursday, August 4, the most recent quarterly earnings report for Progyny (NASDAQ: PGNY) was made public and made available for analysis. The company reported earnings per share (EPS) for the quarter at $0.09, which is $0.07 more than the consensus estimate of $0.02 per share. The revenue the company brought in during the quarter was $195 million, which is significantly higher than the forecasted revenue of $190.51 million that was made for the company. The return on equity for Progyny was 17.11 percent, while the net margin for the company was 7.39 percent. Compared to the current quarter, the previous quarter’s sales of the company’s products and services saw a 51.5% increase. The business made a profit of $0.19 per share during the same period the year before, compared to the current year. According to research analysts, the earnings forecast for Progyny for this year is 0.2 cents per share. This forecast was derived from the company’s financial statements.
The benefits management company, Progyny, Inc., focuses most of its efforts on providing family planning and fertility benefits for employers in the United States. Its solution for fertility benefits includes:
AA plan design that is different from what competitors offe.
AA member support service that works like a concierg.
Atwork of fertility specialists.
Source: beststocks.com
